{"id":444,"date":"2025-12-15T08:59:39","date_gmt":"2025-12-15T08:59:39","guid":{"rendered":"https:\/\/mrna.creative-biolabs.com\/blog\/?p=444"},"modified":"2025-12-15T08:59:39","modified_gmt":"2025-12-15T08:59:39","slug":"beyond-the-liver-a-new-one-component-mrna-delivery-system-revolutionizes-cancer-vaccines","status":"publish","type":"post","link":"https:\/\/mrna.creative-biolabs.com\/blog\/beyond-the-liver-a-new-one-component-mrna-delivery-system-revolutionizes-cancer-vaccines\/","title":{"rendered":"Beyond the Liver: A New One-Component mRNA Delivery System Revolutionizes Cancer Vaccines"},"content":{"rendered":"

The remarkable clinical success of mRNA vaccines in preventing COVID-19, driven by their ability to rapidly induce robust immune responses, has paved the way for new frontiers in medicine. This success has specifically propelled the development of mRNA-based cancer vaccines, a promising strategy designed to stimulate potent and specific anti-tumor immune responses.<\/span><\/p>\n

However, a major hurdle remains: effectively delivering antigen-encoding mRNA to antigen-presenting cells (APCs) within lymphoid organs to trigger comprehensive innate and adaptive immunity.<\/span><\/p>\n

The Challenge with Traditional LNPs<\/strong><\/span><\/p>\n

Lipid nanoparticles (LNPs) represent the most advanced delivery system for mRNA vaccines. Despite their success, traditional LNPs have a significant limitation\u2014they tend to accumulate in the liver following systemic administration. Furthermore, classic LNPs rely on a complex four-component formulation (ionizable lipids, cholesterol, phospholipids, and PEG-lipids).<\/span><\/p>\n

While researchers have attempted to target the spleen using anionic lipids or novel ionizable lipids, a simpler, more efficient solution was needed.<\/span><\/p>\n

Enter OncoLRC: A Spleen-Tropic Solution<\/strong><\/span><\/p>\n

Recently, a research team led by Qiu Min at the Human Phenome Institute, Fudan University, published a study in Advanced Science<\/em> titled “A Rationally Engineered Spleen-Tropic One-Component Lipid-mRNA Complex (OncoLRC) for Cancer Vaccines”<\/em>.<\/span><\/p>\n

The team developed OncoLRC<\/strong>, a rationally engineered, single-component delivery system based on dimethylamine (DMA) lipidoids. This innovative platform efficiently targets mRNA to APCs in the spleen, activating a robust anti-tumor immune response.<\/span><\/p>\n

\"\"<\/p>\n

Fig.1 Mechanism underlying the cellular uptake of OncoLRC.1<\/sup><\/span><\/p>\n

How It Works: Rational Engineering<\/strong><\/span><\/p>\n

The researchers synthesized a series of lipidoids using DMA as the ionizable headgroup and identified H2T7<\/strong> as the core candidate due to its high splenic expression.<\/span><\/p>\n

Through a “four-step optimization method,” they simplified the formulation. They adjusted the lipid-to-mRNA ratio and removed auxiliary components like cholesterol and PEG. The result was a concise, single-component system named OncoLRC.<\/span><\/p>\n

Key Advantages and Results<\/strong><\/span><\/p>\n